Two injections, two different knee problems

When patients compare ChondroFiller and Arthrosamid, the question is usually framed as 'which one is better?' — but that framing misses the point. These are not two versions of the same injection competing for the same job. They address different structures inside the knee and are suited to different types of damage.

ChondroFiller works at the cartilage surface — the smooth, load-bearing tissue that covers the ends of the bones. It is designed for a focal patch of damage: a discrete, contained area where cartilage has worn through or been injured. Arthrosamid, by contrast, is injected into the joint lining (the synovial membrane) and is designed for diffuse, widespread joint wear — the kind of generalised deterioration seen in moderate-to-severe osteoarthritis.

Because they act on entirely different anatomical structures, the better question is not 'which is superior?' but 'which one matches my knee's damage pattern?' In some cases, where a patient has both a focal defect and broader joint wear, both treatments may be appropriate together.

The essential first step is an MRI scan and a specialist review — not a product choice.

ChondroFiller: what it does and who it suits

Injected as an outpatient under ultrasound guidance, ChondroFiller is a cell-free Type I collagen scaffold — a CE-marked Class III medical device manufactured by Meidrix Biomedicals. Once placed into the defect, the liquid gel sets within approximately three to five minutes, forming a three-dimensional matrix inside the damaged area. The process is called acellular matrix-induced chondrogenesis: the scaffold itself contains no cells, but it draws in the patient's own progenitor cells from surrounding tissue, which differentiate and deposit new cartilage material as the collagen is gradually resorbed.

Who is a suitable candidate?

The right patient for ChondroFiller has a discrete, contained Grade III–IV chondral defect — generally up to around 3 cm² — with healthy cartilage borders confirmed on MRI. Because the treatment depends on the body's own repair response, it tends to suit younger or more active patients whose surrounding cartilage remains structurally intact. Widespread, diffuse joint degeneration is a different clinical picture and calls for a different approach.

What the published evidence shows

Across four published knee studies, ChondroFiller consistently produces approximately 30-point improvements in IKDC scores, well above the 16.7-point threshold considered clinically meaningful. The Jerosch et al. post-market follow-up study reported a mean improvement of 32.4 points, sustained at three-year review. MRI MOCART scores in European multicentre data range from 81.6 to 84.3, indicating greater than 80% defect filling and good integration with surrounding native cartilage. Across published series, 70–85% of treated patients achieve meaningful symptom relief at three to five years. Most of this evidence is manufacturer-sponsored; independent long-term randomised data remain limited.

Tissue maturation takes months, not weeks — gains typically appear in the first six months and plateau around twelve. ChondroFiller is not NHS-funded and is not FDA-approved; UK patients access it on a self-pay basis.

Arthrosamid: what it does and who it suits

Arthrosamid is a 2.5% cross-linked polyacrylamide hydrogel — 97.5% water — injected into the synovial space under image guidance as an outpatient procedure under local anaesthesia. Unlike ChondroFiller, it does not work at the cartilage surface and does not promote cartilage regeneration. Its role is mechanical: once injected, the hydrogel integrates sub-synovially within approximately 10–14 days, forming a permanent cushioning layer within the joint lining. A low-level macrophage-mediated response facilitates that integration and is also associated with a reduction in intra-articular inflammation.

Because the hydrogel is non-biodegradable, it remains in the joint long-term — a factual characteristic patients should weigh as part of their decision, neither a particular advantage nor a drawback in itself.

Who is a suitable candidate?

Arthrosamid is matched to patients with diffuse moderate-to-severe knee osteoarthritis — Kellgren-Lawrence grade III–IV — where wear is widespread across the joint rather than confined to a focal patch. It is often considered where hyaluronic acid injections have not provided adequate or lasting relief.

What the evidence shows

Manufacturer-sponsored research — including Bliddal et al. open-label studies published at six months (2021) and twelve months (J Orthop Surg Res, 2024;19:274) — reports meaningful pain reduction in 70–80% of patients, sustained for up to five years from a single injection. Pain relief typically begins around week 4. Independent long-term randomised data are limited. Arthrosamid is available on a self-pay basis in the UK, is not NHS-funded, and does not have FDA approval.

How clinicians decide which one fits your knee

Assessment begins with MRI — but reading the scan is the start of a clinical conversation, not the end of it.

A well-defined cartilage crater with healthy surrounding borders points toward ChondroFiller as the candidate treatment. Defect size is a hard boundary here: lesions significantly beyond approximately 3 cm², or those set within compromised cartilage, fall outside the typical indication regardless of how the patient feels. By contrast, diffuse, compartment-wide degeneration — cartilage thinning spread across multiple joint surfaces rather than a contained patch — shifts the conversation toward Arthrosamid, where the aim is sustained pain reduction rather than structural repair. No hydrogel cushion can repair a focal structural defect; equally, a collagen scaffold placed into a diffuse, degenerated joint has no healthy architecture to work with.

When the picture is mixed — a discrete lesion sitting within a joint that also shows broader OA changes — both treatments may be relevant, each operating through entirely different mechanisms on different anatomical structures. The decision then turns on which problem is driving symptoms, not on a preference for one product over the other.

Age and activity profile provide a secondary lens. A younger, more active patient with a focal defect has cartilage architecture worth supporting toward repair. An older patient whose primary concern is managing day-to-day pain in a more widely worn joint represents a different clinical profile and a different set of priorities.

No head-to-head randomised trial yet compares the two products directly, so selection rests on imaging findings, symptom pattern, and clinical judgement. A first assessment appointment maps the picture; the treatment decision typically emerges from reviewing those findings alongside the patient's functional goals and expectations.

What each treatment involves and how long results last

The practical gap between how quickly each treatment works matters more than raw outcome figures suggest — particularly when both are being considered for the same knee.

ChondroFiller's scaffold supports repair over months. Gains typically emerge across the first six months and consolidate toward the 12-month mark, with published follow-up extending to three to five years. Critically, the collagen matrix is gradually resorbed and replaced by the patient's own repair tissue; no permanent material remains in the joint. Future imaging or clinical reassessment therefore reflects the body's own response rather than the continued presence of a durable implant.

Arthrosamid's trajectory runs differently. Integration is completed within a shorter window, and pain relief typically begins building from around the fourth week. Because the hydrogel is designed to remain in the joint permanently, surgeons assessing or treating the joint at any later stage will encounter a joint that has been durably modified at the synovial lining level — a practical consideration worth raising at an initial assessment appointment, not just weighing after the fact.

Where both products are clinically appropriate for the same knee, the treating consultant's assessment of which problem is driving symptoms, and which intervention is most time-sensitive, informs the sequence rather than the two treatments necessarily starting simultaneously.

On evidence quality: published outcomes for both are encouraging, but the majority of studies are manufacturer-supported or single-arm open-label designs. Asking a specialist what the evidence base looks like for your specific defect pattern and OA grade — not the generic headline figures — is a more useful starting point than comparing headline success rates between two treatments that are, ultimately, doing different jobs inside the joint.

Getting a specialist knee assessment without a referral

Deciding between these two treatments — or whether either applies — requires a structured clinical assessment rather than a self-directed comparison of product descriptions.

A consultant-led assessment typically begins with a review of existing knee MRI, or arranges new imaging if none is current. The central questions are whether damage is focal or diffuse, whether surrounding cartilage borders are healthy enough to support a regenerative scaffold, and what the patient's functional goals are. Where AI-assisted cartilage analysis such as onMRI™ is available, it can help characterise lesion depth, size, and surrounding tissue quality — factors that directly bear on ChondroFiller or Arthrosamid suitability.

Practical questions worth raising at any such assessment include: what does the MRI show about defect size and pattern; is the joint suitable for one treatment, both, or neither; and what does the recovery timeline look like relative to current activity demands?

Lincolnshire Knee is part of the MSK Doctors group and accepts patients directly, without a GP referral and without NHS-style waiting lists. Assessment clinics are available in Sleaford (NG34) and Grantham (NG31). Book at lincolnshireknee.co.uk.